Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1458-1462

  Shoen, Carolyn M ^a   Chase, Sharon E ^b   Destefano, Michelle S ^a   Harpster, Tami S ^b   Chmielewski, Alex J ^b   Cynamon, Michael H ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFALAZIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; MICE; RIFAMYCINS; TUBERCULOSIS;

EID: 0034118231     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1458-1462.2000     Document Type: Article

References (14)

1. British Thoracic Society. 1984. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br. J. Dis. Chest 78:330-336.
2. Brooks, J. V., and I. M. Orme. 1998. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob. Agents Chemother. 42:3047-3048.
3. Daniel, W. W. 1978. The Fisher exact test, p. 110-114. In Applied nonparametric statistics. Houghton Mifflin Co., Boston, Mass.
4. Fox, W. 1979. The chemotherapy of pulmonary tuberculosis: a review. Chest 76S:785-796.
5. Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. 1998. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am. J. Respir. Crit. Care Med. 157:1436-1440.
6. Kelly, B. P., S. K. Furney, M. T. Jessen, and I. M. Orme. 1996. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2809-2812.
7. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38:2245-2248.
8. Klemens, S. P., and M. H. Cynamon. 1996. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murinc model. Antimicrob. Agents Chemother. 40:298-301.
9. Mitchison, D. A. 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2:10-15.
10. Reddy, M. V., J. Luna-Herrera, D. Daneluzzi, and P. R. J. Gangadharam. 1996. Chemotherapeutic activity of benzoxaziriorifamvcin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle Lung Dis. 77:154-159.
11. Singapore Tuberculosis Service/British Medical Research Council. 1979. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 119:579-585.
12. Snider, D. E., J. Rogowski, M. Zierski, E. Bek, and M. W. Long. 1982. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am. Rev. Respir. Dis. 125: 265-267.
13. Snider, D. E., J. Graczyk, E. Bek, and J. Rogowski. 1984. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am. Rev. Respir. Dis. 130:1091-1094.
14. Yamamoto, T., R. Amitani, K. Suzuki, E. Tanaka, T. Murayama, and F. Kuze. 1996. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:426-428.